Literature DB >> 25527748

Palmitoleic acid is elevated in fatty liver disease and reflects hepatic lipogenesis.

Joseph J Lee1, Jennifer E Lambert1, Yelena Hovhannisyan1, Maria A Ramos-Roman1, Justin R Trombold1, David A Wagner1, Elizabeth J Parks1.   

Abstract

BACKGROUND: Biochemical evidence has linked the coordinate control of fatty acid (FA) synthesis with the activity of stearoyl-CoA desaturase-1 (SCD1). The ratio of 16:1n-7 to 16:0 [SCD1₁₆] in plasma triacylglycerol FA has been used as an index to reflect liver SCD1₁₆ activity and has been proposed as a biomarker of FA synthesis, although this use has not been validated by comparison with isotopically measured de novo lipogenesis (DNL(Meas)).
OBJECTIVE: We investigated plasma lipid 16:1n-7 and FA indexes of elongation and desaturation in relation to lipogenesis.
DESIGN: In this cross-sectional investigation of metabolism, 24 overweight adults, who were likely to have elevated DNL, consumed D2O for 10 d and had liver fat (LF) measured by magnetic resonance spectroscopy. Very-low-density lipoprotein (VLDL)-triacylglycerols and plasma free FA [nonesterified fatty acids (NEFAs)] were analyzed by using gas chromatography for the FA composition (molar percentage) and gas chromatography-mass spectrometry and gas chromatography-combustion isotope ratio mass spectrometry for deuterium enrichment.
RESULTS: In all subjects, VLDL-triacylglycerol 16:1n-7 was significantly (P < 0.01) related to DNL(Meas) (r = 0.56), liver fat (r = 0.53), and adipose insulin resistance (r = 0.56); similar positive relations were shown with the SCD1₁₆ index, and the pattern in NEFAs echoed that of VLDL-triacylglycerols. Compared with subjects with low LF (3.1 ± 2.7%; n = 11), subjects with high LF (18.4 ± 3.6%; n = 13) exhibited a 45% higher VLDL-triacylglycerol 16:1n-7 molar percentage (P < 0.01), 16% of subjects had lower 18:2n-6 (P = 0.01), and 27% of subjects had higher DNL as assessed by using a published DNL index (ratio of 16:0 to 18:2n-6; P = 0.03), which was isotopically confirmed by DNL(Meas) (increased 2.5-fold; P < 0.01). Compared with 16:0 in the diet, the low amount of dietary 16:1n-7 in VLDL-triacylglycerols corresponded to a stronger signal of elevated DNL.
CONCLUSION: The current data provide support for the use of the VLDL-triacylglycerol 16:1n-7 molar percentage as a biomarker for elevated liver fat when isotope use is not feasible; however, larger-scale confirmatory studies are needed.
© 2015 American Society for Nutrition.

Entities:  

Keywords:  VLDL triacylglycerol; biomarker; lipogenesis; palmitoleic fatty acid; stearoyl-CoA desaturase

Mesh:

Substances:

Year:  2014        PMID: 25527748      PMCID: PMC4266891          DOI: 10.3945/ajcn.114.092262

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  59 in total

Review 1.  De novo lipogenesis in humans: metabolic and regulatory aspects.

Authors:  M K Hellerstein
Journal:  Eur J Clin Nutr       Date:  1999-04       Impact factor: 4.016

2.  Diet fat composition alters membrane phospholipid composition, insulin binding, and glucose metabolism in adipocytes from control and diabetic animals.

Authors:  C J Field; E A Ryan; A B Thomson; M T Clandinin
Journal:  J Biol Chem       Date:  1990-07-05       Impact factor: 5.157

3.  Fatty acid synthesis de novo in adipose tissue from obese subjects on a hypercaloric high-carbohydrate diet.

Authors:  L Sjöström
Journal:  Scand J Clin Lab Invest       Date:  1973-12       Impact factor: 1.713

4.  Human fatty acid synthesis is stimulated by a eucaloric low fat, high carbohydrate diet.

Authors:  L C Hudgins; M Hellerstein; C Seidman; R Neese; J Diakun; J Hirsch
Journal:  J Clin Invest       Date:  1996-05-01       Impact factor: 14.808

5.  Use of stable isotopes to study fatty acid and lipoprotein metabolism in man.

Authors:  J T Brenna
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  1997-10       Impact factor: 4.006

6.  Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.

Authors:  D R Matthews; J P Hosker; A S Rudenski; B A Naylor; D F Treacher; R C Turner
Journal:  Diabetologia       Date:  1985-07       Impact factor: 10.122

7.  The effect of a low-cholesterol, high-polyunsaturate diet on serum lipid levels, apolipoprotein B levels and triglyceride fatty acid composition.

Authors:  P N Durrington; C H Bolton; M Hartog; R Angelinetta; P Emmett; S Furniss
Journal:  Atherosclerosis       Date:  1977-08       Impact factor: 5.162

8.  Increase in long-chain polyunsaturated fatty acid n - 6/n - 3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease.

Authors:  Julia Araya; Ramón Rodrigo; Luis A Videla; Lilian Thielemann; Myriam Orellana; Paulina Pettinelli; Jaime Poniachik
Journal:  Clin Sci (Lond)       Date:  2004-06       Impact factor: 6.124

Review 9.  Metabolism of dietary stearic acid relative to other fatty acids in human subjects.

Authors:  E A Emken
Journal:  Am J Clin Nutr       Date:  1994-12       Impact factor: 7.045

10.  Hepatic secretion of VLDL fatty acids during stimulated lipogenesis in men.

Authors:  A Aarsland; R R Wolfe
Journal:  J Lipid Res       Date:  1998-06       Impact factor: 5.922

View more
  67 in total

1.  MUFAs.

Authors:  Douglas G Mashek; Chaodong Wu
Journal:  Adv Nutr       Date:  2015-05-15       Impact factor: 8.701

2.  Gluconeogenesis and risk for fasting hyperglycemia in Black and White women.

Authors:  Stephanie T Chung; Amber B Courville; Anthony U Onuzuruike; Mirella Galvan-De La Cruz; Lilian S Mabundo; Christopher W DuBose; Kannan Kasturi; Hongyi Cai; Ahmed M Gharib; Peter J Walter; H Martin Garraffo; Shaji Chacko; Morey W Haymond; Anne E Sumner
Journal:  JCI Insight       Date:  2018-09-20

3.  Association between Nicotinamide Phosphoribosyltransferase and de novo Lipogenesis in Nonalcoholic Fatty Liver Disease.

Authors:  Bahareh Amirkalali; Masoud Reza Sohrabi; Ali Esrafily; Mahmoud Jalali; Ali Gholami; Payam Hosseinzadeh; Hossein Keyvani; Farzad Shidfar; Farhad Zamani
Journal:  Med Princ Pract       Date:  2017-01-09       Impact factor: 1.927

4.  Hepatocyte-specific, PPARγ-regulated mechanisms to promote steatosis in adult mice.

Authors:  Abigail Wolf Greenstein; Neena Majumdar; Peng Yang; Papasani V Subbaiah; Rhonda D Kineman; Jose Cordoba-Chacon
Journal:  J Endocrinol       Date:  2016-10-31       Impact factor: 4.286

5.  Bromocriptine mesylate improves glucose tolerance and disposal in a high-fat-fed canine model.

Authors:  Mary Courtney Moore; Marta S Smith; Larry L Swift; Anthony H Cincotta; Michael Ezrokhi; Nicholas Cominos; Yahong Zhang; Ben Farmer; Alan D Cherrington
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-05-27       Impact factor: 4.310

6.  Clusters of fatty acids in the serum triacylglyceride fraction associate with the disorders of type 2 diabetes.

Authors:  Luke W Johnston; Zhen Liu; Ravi Retnakaran; Bernard Zinman; Adria Giacca; Stewart B Harris; Richard P Bazinet; Anthony J Hanley
Journal:  J Lipid Res       Date:  2018-07-09       Impact factor: 5.922

Review 7.  Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.

Authors:  Donald B Jump; Kelli A Lytle; Christopher M Depner; Sasmita Tripathy
Journal:  Pharmacol Ther       Date:  2017-07-16       Impact factor: 12.310

Review 8.  Stable isotope-based flux studies in nonalcoholic fatty liver disease.

Authors:  Arthur McCullough; Stephen Previs; Takhar Kasumov
Journal:  Pharmacol Ther       Date:  2017-07-16       Impact factor: 12.310

9.  Hepatic PPARγ Is Not Essential for the Rapid Development of Steatosis After Loss of Hepatic GH Signaling, in Adult Male Mice.

Authors:  Rhonda D Kineman; Neena Majumdar; Papasani V Subbaiah; Jose Cordoba-Chacon
Journal:  Endocrinology       Date:  2016-03-07       Impact factor: 4.736

10.  Impact of dietary fat on the development of non-alcoholic fatty liver disease in Ldlr-/- mice.

Authors:  Donald B Jump; Christopher M Depner; Sasmita Tripathy; Kelli A Lytle
Journal:  Proc Nutr Soc       Date:  2015-08-18       Impact factor: 6.297

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.